From Innovation to Regeneration

Nohla is leading the development of universal, off-the-shelf cell therapies for patients with hematologic malignancies and other critical diseases.


(Our Science)


(Our Products)

Ongoing Phase 2 Trials
Patients Treated w/NLA101
Years of Research
WW Stem Cell Transplants Per Year

Ongoing Trials

Dilanubicel (NLA101) is currently under evaluation in two large randomized, multi-center Phase 2 studies. The first is an ongoing Phase 2b study in the US for patients with acute leukemia, MDS or CML undergoing a myeloablative CBT. The second Phase 2 trial is a global study intended to enroll 220 patients with AML who are at risk for neutropenia following high dose chemotherapy.

Patient Stories

Over 100 patients and counting have been treated with dilanubicel (NLA101) across four clinical trials, bringing hope to those with limited or no treatment options.

Press Releases

Events & Presentations

Nohla’s lead product, dilanubicel (NLA101), is a universal regenerative cell therapy consisting of ex vivo expanded stem and progenitor cells derived from umbilical cord blood, available off the shelf without the need for HLA matching.